Dyno Therapeutics is pioneering an artificial intelligence (AI) powered approach to gene therapy. Using machine learning and quantitative high-throughput in vivo experimentation, we are inventing new ways to design gene vectors with a focus on cell-targeting capsid proteins from adeno-associated virus (AAV), the most widely-used vector for gene therapies.
Our team includes world-class molecular and synthetic biologists, protein engineers and gene therapy scientists working alongside software engineers, data scientists, and AI and machine learning experts. We raised a $100M Series A in 2021 led by a16z to continue expanding our team.
As we create AI-powered gene therapies that enhance the life-changing potential of gene therapies for millions of patients, we believe the future is within reach.